Top-News
Pharmazeutika USA

Kintara Therapeutics News

Aktie
WKN:  A3D08A ISIN:  US49720K2006 US-Symbol:  KTRA
0,1318 €
-0,0068 €
-4,91%
09:40:55 Uhr
Handeln Depot/Watchlist
Aktienanzahl *
1,75 Mio.
Marktkapitalisierung *
242,57 Tsd. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 24.11.2023

Kintara Therapeutics News

11.04.24 - PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVLY, CTLT, SCX, KTRA
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVLY, CTLT, SCX, KTRA PR Newswire
09.04.24 - PR Newswire
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Kintara Biopharma, Inc. - KTRA
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Kintara Biopharma, Inc. - KTRA PR Newswire
08.04.24 - PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MODN, SCX, KTRA
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MODN, SCX, KTRA PR Newswire
05.04.24 - PR Newswire
Kuehn Law Encourages KTRA, ABIO, SWAV, and NS Investors to Contact Law Firm
Kuehn Law Encourages KTRA, ABIO, SWAV, and NS Investors to Contact Law Firm PR Newswire
04.04.24 - PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PIK, CHX, KTRA, ABIO
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PIK, CHX, KTRA, ABIO PR Newswire
03.04.24 - PR Newswire
Shareholder Alert: Ademi LLP investigates whether Kintara Therapeutics, Inc. has obtained a Fair Price in its transaction with TuHURA
Shareholder Alert: Ademi LLP investigates whether Kintara Therapeutics, Inc. has obtained a Fair Price in its transaction with TuHURA PR Newswire
03.04.24 - PR Newswire
Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement
Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement PR Newswire
27.03.24 - PR Newswire
Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab
Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab PR Newswire
14.02.24 - PR Newswire
Kintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results and Provides Corporate Update
Kintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results and Provides Corporate Update PR Newswire
12.02.24 - PR Newswire
Kintara Therapeutics Announces Initiation of REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast Cancer
Kintara Therapeutics Announces Initiation of REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast Cancer PR Newswire
07.12.23 - PR Newswire
Kintara Therapeutics Announces Review of Strategic Alternatives
Kintara Therapeutics Announces Review of Strategic Alternatives PR Newswire
05.12.23 - PR Newswire
Kintara Therapeutics Granted Extension by Nasdaq to Regain Compliance with the Stockholders' Equity Continued Listing Requirement
Kintara Therapeutics Granted Extension by Nasdaq to Regain Compliance with the Stockholders' Equity Continued Listing Requirement PR Newswire
13.11.23 - PR Newswire
Kintara Therapeutics Announces Fiscal 2024 First Quarter Financial Results and Provides Corporate Update
Kintara Therapeutics Announces Fiscal 2024 First Quarter Financial Results and Provides Corporate Update PR Newswire
31.10.23 - PR Newswire
Kintara Therapeutics Announces Preliminary Topline Results From GBM AGILE Study
Kintara Therapeutics Announces Preliminary Topline Results From GBM AGILE Study PR Newswire
11.10.23 - PR Newswire
Kintara Therapeutics to Present at the 8th Annual Dawson James Small Cap Growth Conference
Kintara Therapeutics to Present at the 8th Annual Dawson James Small Cap Growth Conference PR Newswire
02.10.23 - PR Newswire
Kintara Therapeutics to Present at the LD Micro Main Event XVI Conference
Kintara Therapeutics to Present at the LD Micro Main Event XVI Conference PR Newswire
25.09.23 - PR Newswire
Kintara Therapeutics Presents Case Studies of Glioblastoma Patients Treated with VAL-083 at 2023 European Association for Neuro-Oncology Annual Meeting
Kintara Therapeutics Presents Case Studies of Glioblastoma Patients Treated with VAL-083 at 2023 European Association for Neuro-​Oncology Annual Meeting PR Newswire
18.09.23 - PR Newswire
Kintara Therapeutics Announces Fiscal 2023 Year Financial Results and Provides Corporate Update
Kintara Therapeutics Announces Fiscal 2023 Year Financial Results and Provides Corporate Update PR Newswire
05.09.23 - PR Newswire
Kintara Therapeutics to Present at the 2023 European Association for Neuro-Oncology Annual Meeting
Kintara Therapeutics to Present at the 2023 European Association for Neuro-​Oncology Annual Meeting PR Newswire
17.08.23 - PR Newswire
Kintara Therapeutics to Host Virtual KOL Event on VAL-083, A Potential First-in-Class Small Molecule Chemotherapeutic for Glioblastoma, on August 21, 2023
Kintara Therapeutics to Host Virtual KOL Event on VAL-083, A Potential First-​in-Class Small Molecule Chemotherapeutic for Glioblastoma, on August 21, 2023 PR Newswire

Newssuche

Videos

07.05.24 -3,00%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: NG8K9X Hebel: 26 Laufzeit: OpenEnd Einstieg: Market ... Mehr »